In conclusion, elevated CXCR5 and LAG‐3 expression on peripheral blood CD8+ T cells plays a pivotal role in DLBCL progression and prognosis, making these markers potential therapeutic targets or prognostic indicators. This evidence concerns the gene CXCR5 and diffuse large B-cell lymphoma.